• Explore /
  • Poster
  • / INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced esophagogastric cancer (AOGC)—A study by the Australasian Gastrointestinal Trials Group (AGITG).

INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced esophagogastric cancer (AOGC)—A study by the Australasian Gastrointestinal Trials Group (AGITG).

Abstract Poster

Authors

Nick Pavlakis

Nick Pavlakis

Royal North Shore Hospital, Sydney University, Sydney, Australia

Nick Pavlakis , David Goldstein , Katrin Marie Sjoquist , Andrew Martin , Eric Tsobanis , Sonia Yip , Jenny Shannon , Matthew E. Burge , Michelle F. Cronk , Niall C. Tebbutt , Andrew Strickland , Lara Rachel Lipton , Timothy Jay Price , Louise M. Nott , Dean Laurence Harris , Margot J. Burnell , Thierry Alcindor , Yung-Jue Bang , Yoon-Koo Kang , Christopher J. O'Callaghan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

ACTRN12612000239864

Citation

J Clin Oncol 31, 2013 (suppl; abstr TPS4157)

DOI

10.1200/jco.2013.31.15_suppl.tps4157

Abstract #

TPS4157

Poster Bd #

33C

Abstract Disclosures

Similar Posters

First Author: Katrin Marie Sjoquist

First Author: Nick Pavlakis

First Author: Anuj Kishor Patel

First Author: Hirokazu Shoji